In the preclinical and clinical studies of Alzheimer’s disease and Parkinson’s disease, its neuroprotective functions were proved: GLP-1R agonists exerted anti-oxidant damage, neurotrophic properties and anti-apoptosis roughly through cAMP/PKA and PI3K/Akt signaling pathways, and effectively protect dopaminergic neurons and improve cognition and motor functions (Athauda and Foltynie, 2018; Batista et al., 2019). The gene discussed is AKT1; the disease is early-onset autosomal dominant Alzheimer disease.